Lynch Syndrome Linked to Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor

A 29-year-old woman who had already survived colon cancer at an unusually young age has become the center of one of the most molecularly intricate cancer cases ever documented: a metastatic pancreatic neuroendocrine tumor arising in the setting of Lynch syndrome, the most common hereditary cancer predisposition condition in the world. The case, published in Clinical Case Reports, not only documents what researchers believe is the first confirmed intermediate-grade, mismatch-repair-deficient pancreatic neuroendocrine tumor with hepatic metastases in a young adult with Lynch syndrome, but also reveals a striking biological surprise—the primary tumor and its liver metastases displayed opposite patterns of mismatch repair protein expression, a form of heterogeneity that carries direct consequences for treatment selection and for how clinicians think about hereditary cancer evolution.

Lynch syndrome, historically known as hereditary non-polyposis colorectal cancer, affects roughly 1 in 279 people globally and is caused by inherited, pathogenic variants in one of the DNA mismatch repair genes—MLH1, MSH2, MSH6 or PMS2—or in the EPCAM gene, whose deletions silence MSH2. These genes encode the cellular machinery that proofreads DNA during replication; when one copy is inherited in a damaged form, a single “second hit” in a somatic cell is enough to cripple repair entirely, allowing mutations to accumulate at breathtaking speed. The result is a dramatically elevated lifetime risk of colorectal and endometrial cancers, along with elevated risks of tumors of the stomach, ovary, urinary tract, small bowel, pancreas, biliary tract, skin and brain. Mismatch-repair-deficient tumors are characterized by microsatellite instability and high tumor mutational burden, molecular signatures that shape both diagnosis and therapy.

The patient’s story began in April 2014, when she presented with abdominal discomfort, iron deficiency anemia and stool occult blood against a family history dense with colorectal cancer that met both the Bethesda and Amsterdam clinical criteria. Colonoscopy revealed a mass in the ascending colon, and she underwent a total colectomy with proximal proctectomy, ileorectal anastomosis and lymph node dissection. Pathology showed a 6-centimeter, low-grade, mucin-producing adenocarcinoma staged pT3N0. Immunohistochemistry demonstrated complete loss of the MLH1 and PMS2 proteins, and polymerase chain reaction testing with the Bethesda panel confirmed high-level microsatellite instability. Critically, the team then performed pyrosequencing on formalin-fixed tissue to exclude the sporadic route to mismatch repair deficiency: MLH1 promoter methylation was absent and BRAF V600E was wild-type, pointing strongly toward an inherited defect rather than an acquired one.

Germline panel testing subsequently identified the c.131C>A (p.Ser44Tyr) variant in the MLH1 gene. At the time of testing in 2017, the variant was classified as a variant of uncertain significance, but the accumulated clinical, histopathological and molecular evidence was sufficient to diagnose Lynch syndrome and enroll the patient in active surveillance. The evidence base for the variant matured quickly: pathogenicity data submitted to the Leiden Open Variation Database supported reclassification, and by 2018 p.Ser44Tyr was formally designated pathogenic, confirming the diagnosis. She received six months of adjuvant XELOX chemotherapy, a decision made in 2014 before current guidelines—which favor observation alone for deficient mismatch repair stage II colon cancer—were fully established, owing to her young age and extensive family history.

For seven years she remained symptom-free. Then, at age 36 in August 2021, pruritus and a sharply elevated alkaline phosphatase of 1091 signaled biliary obstruction. Ultrasound and contrast-enhanced computed tomography revealed a 23 by 24 by 27 millimeter mass in the head of the pancreas compressing the common bile duct, without invasion of the superior mesenteric artery. Endoscopic ultrasound-guided fine-needle aspiration of the mass and a hilar lymph node yielded a well-differentiated neuroendocrine neoplasm. Immunostaining showed diffuse synaptophysin positivity, focal chromogranin A expression and a Ki-67 proliferation index of 5 percent—a Grade 2 pancreatic neuroendocrine tumor under the WHO 2019 classification. She underwent a Whipple procedure, and the resected specimen confirmed a 2.7-centimeter Grade 2 tumor with peripancreatic soft tissue extension and 28 negative lymph nodes.

The molecular bombshell came from the resected pancreatic tumor itself: immunohistochemistry demonstrated loss of MLH1 and PMS2 expression within the neuroendocrine cells, an extraordinarily unusual finding in this tumor type. The result was verified by an independent second laboratory, establishing the tumor as genuinely mismatch-repair-deficient and arising in the context of Lynch syndrome. A literature review by the case authors identified only three previously reported pancreatic neuroendocrine tumors in Lynch syndrome patients, none of them metastatic, making this young woman’s presentation the first documented case of an intermediate-grade, deficient-repair pancreatic neuroendocrine tumor with confirmed liver metastases in this population. For context, mismatch repair carriers face roughly a 6.2 percent lifetime pancreatic cancer risk through age 80, versus 1.6 percent in the general population—but those malignancies are almost always ductal adenocarcinomas, not neuroendocrine tumors.

Surveillance followed the North American and European Neuroendocrine Tumor Society guidelines, with contrast-enhanced multiphasic MRI every six months. When subtle hepatic changes appeared on postoperative ultrasound, the team escalated to gallium-68 DOTATATE positron emission tomography at six months post-resection—a deviation from routine surveillance justified by the high-risk context. The functional scan, which exploits the dense somatostatin receptors that neuroendocrine tumors display on their surfaces, revealed multiple liver lesions across both lobes plus mesenteric soft tissue enhancement, highly suggestive of metastatic disease. Core needle biopsy of a hepatic lesion confirmed a well-differentiated Grade 1 metastatic neuroendocrine tumor with a Ki-67 index of just 1 percent.

Then came the twist. Immunohistochemistry on the liver metastasis showed intact—retained—MLH1 and PMS2 expression, directly contradicting the complete loss seen in the pancreatic primary. To resolve whether the two tumors were even related, the team performed next-generation sequencing on tissue from both sites using a comprehensive cancer panel. The sequencing confirmed the identical germline MLH1 c.131C>A variant in both lesions, establishing a clonal relationship, while revealing discordant somatic mutational profiles—each tumor had accumulated its own distinct additional alterations. No MLH1 reversion mutations were found in the metastasis. The authors propose several mechanisms: subclonal selection during metastatic dissemination may have favored clones that retained functional mismatch repair through epigenetic modification; the “second hit” disabling the wild-type MLH1 allele may have operated differently at the primary versus metastatic site; or the liver microenvironment’s immune surveillance and metabolic pressures may have selected for clones with intact DNA repair.

These findings directly shaped therapy. Although immune checkpoint blockade with pembrolizumab has transformed care for mismatch-repair-deficient solid tumors, well-differentiated neuroendocrine tumors typically harbor immunologically “cold” microenvironments, and—most decisively—the actual therapeutic target, the metastatic disease, had intact repair machinery and would likely not respond to checkpoint inhibitors. The multidisciplinary tumor board instead followed neuroendocrine tumor consensus guidelines, starting octreotide LAR at 30 milligrams every 28 days, a somatostatin analog appropriate for an asymptomatic patient with low tumor burden and low proliferative index. At three-month follow-up in June 2022, imaging documented progression under RECIST 1.1 criteria—a 35 percent increase in the sum of target lesions plus new hepatic lesions—prompting escalation to peptide receptor radionuclide therapy with lutetium-177 vipivotide tetraxetan (Lutathera) at 7.4 gigabecquerels every 8 weeks for four cycles, with octreotide continued between infusions.

The outcome has been remarkable. The patient has maintained durable disease control for more than three years, remaining clinically well and symptom-free, with serial gallium-68 DOTATATE scans showing the liver lesions shrinking steadily across 12- and 18-month follow-up imaging. She now undergoes positron emission tomography surveillance every six months. The case authors emphasize several broader lessons: Lynch syndrome surveillance may warrant expansion beyond the traditional colorectal and endometrial focus in high-risk individuals, hereditary cancer registries should systematically capture atypical tumor presentations to refine genotype-phenotype correlations, and comprehensive molecular profiling—including immunohistochemistry, microsatellite instability testing, promoter methylation analysis, BRAF genotyping and paired next-generation sequencing of primary and metastatic lesions—is indispensable when hereditary cancer syndromes produce unexpected tumors. As metachronous malignancies continue to emerge in Lynch syndrome carriers decades after their first diagnoses, this single patient’s journey from colectomy to Whipple procedure to radioligand therapy illustrates both the power and the unfinished questions of precision oncology—particularly the enigma of why two tumors from the same founding clone can look, behave and respond so differently.